<DOC>
	<DOCNO>NCT01032850</DOCNO>
	<brief_summary>This research study evaluate Sorafenib ( Nexavar® ) Capecitabine ( Xeloda® ) see follow : - effective combination study drug treat HCC - long subject respond study drug - type side effect expect , - severe side effect All subject study receive : - Sorafenib twice day mouth - Capecitabine twice day mouth Treatment give 28-day treatment cycle . Subjects take sorafenib every day cycle . Subjects take capecitabine day 1-7 15-21 cycle</brief_summary>
	<brief_title>Sorafenib With Capecitabine Patients With Measurable Hepatocellular Carcinoma</brief_title>
	<detailed_description>Hepatocellular carcinoma ( HCC ) , also know primary liver cancer , common form liver cancer responsible 80 percent primary malignant liver tumor adult . It fifth common cancer world . HCC disproportionately affect men , four time many men develop disease woman . In 2002 , approximately 626,000 case HCC report worldwide ( 15,000 United States 53,600 Europe ) , 600,000 death ( 13,000 Americans 57,000 Europeans ) due HCC report . The five-year relative survival rate seven percent . The Gem-Ox regimen use treatment pancreatic cancer encourage result . Preliminary result Gem-Ox combination encourage well.Based observation possibility add bevacizumab , monoclonal antibody VEGF , study investigator . However , combination GEM-OX bevacizumab unlikely tolerate HCC patient Child-Pugh class B C liver cirrhosis especially significant thrombocytopenia.It would seem therefore agent could tolerate cirrhotic patient advanced HCC would include capecitabine , erlotinib sorafenib . We propose phase II trial sorafenib + capecitabine combination patient HCC advance liver cirrhosis platelet count ≥ 40,000 Child-Pugh ( C-P ) class A-and B liver cirrhosis life expectancy ≥16 week .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologic diagnosis hepatocellular carcinoma The lesion lesion resectable curative intent . Prior locoregional treatment ( resection , RFA , chemoembolization ) allow . Adequate bone marrow function : Absolute neutrophil count ( AGC ) &gt; 1500/µL Platelet count &gt; 60,000 /µL Renal function : Serum creatinine &lt; 2.0 mg/dl , calculate CCT &gt; 30 mL/min . Hepatic function : ( Patients ChildPugh ( CP ) class AB ) Bilirubin &lt; 2.8 mg/dl ( provide ChildPugh class liver cirrhosis A B ( 7 ) ( ie . The ChildPugh score 7 point ) ALT AST ≤ 5.0 time ULN • Hemoglobin &gt; 8.5 g/dl ECOG/Zubrod/SWOG Performance Status = 0 &gt; 1 Life expectancy &gt; 16 week Male female ' age &gt; 18 year Patients childbearing potential must use effective mean contraception . INR &lt; 1.5 PT/PTT within normal limit . Any prior systemic therapy include chemotherapy target agent Uncontrolled ascites define easily control stable dos diuretic . Pregnant lactating female Cardiac disease : Congestive heart failure &gt; class II NYHA . Patients must unstable angina ( anginal symptom rest ) new onset angina ( begin within last 3 month ) myocardial infarction within past 6 month . Uncontrolled ' clinically significant dysrhythmia History prior malignancy within prior 3 year , exception nonmelanoma carcinoma skin , carcinoma situ cervix breast , Rai Stage I chronic lymphocytic leukemia superficial bladder cancer . Prior radiotherapy indicator lesion unless objective evidence tumor growth lesion Uncontrolled metastatic disease central nervous system Radiotherapy within 2 week Cycle 1 ' Day 1 Surgery within 2 week Cycle 1 ' Day 1 Any co morbid condition ' view attend physician ' render patient high risk treatment complication . Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management . Known human immunodeficiency virus ( HIV ) infection . Patients chronic Hepatitis B C infection eligible . Active clinically serious infection &gt; CTCAE Grade 2 . Thrombolic embolic event cerebrovascular accident include transient ischemic attack within past 6 month . Pulmonary hemorrhage/bleeding event &gt; CTCAE Grade 2 within 4 week first dose study drug . Any hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 week first dose study drug . Serious nonhealing wound , ulcer , bone fracture . Evidence history bleed diathesis coagulopathy . Use St. John 's Wort rifampin ( rifampicin ) . Known suspected allergy sorafenib agent give course trial . Any condition impair patient 's ability swallow whole pill . Any malabsorption problem .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>INST 0820</keyword>
	<keyword>sorafenib</keyword>
	<keyword>capecitabine</keyword>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>lung</keyword>
	<keyword>nexavar</keyword>
	<keyword>xeloda</keyword>
	<keyword>liver cancer</keyword>
</DOC>